ReviewExpert review of vaccines2012
Prime-boost approaches to tuberculosis vaccine development.
Review in Expert review of vaccines, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.Frontiers in immunology · 2022Pooled it
- Vaccine against tuberculosis: what's new?BMC infectious diseases · 2014Pooled it
- Novel Multistage SubunitVaccines · 2025Article
- Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE.BMC infectious diseases · 2025Article
- Comparative immunogenicity study of two different types of tuberculosis vaccines based on a heterologous boosting strategy.Archives of microbiology · 2025Article
- Possible Anti-Pain Vaccines: A Narrative Review of Emerging Strategies and Clinical Prospects.Vaccines · 2025Review
- Intranasal BCG vaccination induces systemic and pulmonary mucosal immune responses against tuberculosis in a goat model.Frontiers in immunology · 2025Article
- Next-generation vaccines against bacterial pathogens: mRNA and beyond.Frontiers in immunology · 2025Review
- Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models.Frontiers in immunology · 2025Article
- Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal.Heliyon · 2024Review
- Article
- Heterologous Prime-Boost Immunization with DNA Vaccine and Modified Recombinant Proteins Enhances Immune Response againstVaccines · 2022Article
- Self-adjuvanting nanovaccines boost lung-resident CD4NPJ vaccines · 2022Article
- Photochemically-Mediated Inflammation and Cross-Presentation ofFrontiers in immunology · 2022Article
- Progressive Host-Directed Strategies to Potentiate BCG Vaccination Against Tuberculosis.Frontiers in immunology · 2022Review
- Recombinant AhpC antigen fromTurkish journal of biology = Turk biyoloji dergisi · 2022Article
- CFP10-loaded PLGA nanoparticles as a booster vaccine confer protective immunity againstBioImpacts : BI · 2022Article
- Cyclic di-AMP as endogenous adjuvant enhanced BCG-induced trained immunity and protection againstFrontiers in immunology · 2022Article
- Recombinant BCGs for tuberculosis and bladder cancer.Vaccine · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Four individuals die from active TB disease each minute, while at least 2 billion are latently infected and at risk for disease reactivation. BCG, the only licensed TB vaccine, is effective in preventing childhood forms of TB; however its poor efficacy in adults, emerging drug-resistant TB strains and tedious chemotherapy regimes, warrant the development of novel prophylactic measures. Designing safe and effective vaccines against TB will require novel approaches on several levels, including the administration of rationally selected mycobacterial antigens in efficient delivery vehicles via optimal immunization routes. Given the primary site of disease manifestation in the lungs, development of mucosal immunization strategies to generate protective immune responses both locally, and in the circulation, may be important for effective TB prophylaxis. This review focuses on prime-boost immunization strategies currently under investigation and highlights the potential of mucosal delivery and rational vaccine design based on systems biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.